Inserm Transfert, established in 2000, is the private subsidiary of Inserm, operating under a Public Service Concession. Specializing in technology transfer within the life sciences, it manages the economic and societal value creation of Inserm’s research innovations. The company offers a comprehensive range of assets, including access to expert scientists and clinicians, as well as innovations derived from basic, translational, and clinical research. Its strategic areas of innovation encompass digital therapeutics, artificial intelligence, health data, and various therapeutic modalities such as antibodies and cell therapies. Inserm Transfert is committed to supporting researchers and industry partners by co-developing customized programs, leveraging patient cohorts, and facilitating collaborative research to advance human health.